RT Journal Article
T1 Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
A1 Ribera, Jordi
A1 Granada, Isabel
A1 Morgades, Mireia
A1 González, Teresa
A1 Ciudad, Juana
A1 Such, Esperanza
A1 Calasanz, María-José
A1 Mercadal, Santiago
A1 Coll, Rosa
A1 González-Campos, José
A1 Tormo, Mar
A1 García-Cadenas, Irene
A1 Gil, Cristina
A1 Cervera, Marta
A1 Barba, Pere
A1 Costa, Dolors
A1 Ayala, Rosa
A1 Bermúdez, Arancha
A1 Orfao, Alberto
A1 Ribera, Josep-Maria
A1 Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH)
K1 acute lymphoblastic leukaemia
K1 adults
K1 cytogenetic alterations
K1 prognosis
K1 t(1;19)(q23;p13)/TCF3-PBX1
AB The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).
YR 2021
FD 2021-09-21
LK http://hdl.handle.net/10668/18532
UL http://hdl.handle.net/10668/18532
LA en
DS RISalud
RD Apr 11, 2025